The time has come to revolutionize cancer treatment!
Hi everyone,
I’ve been following Thor Medical (TRMED) for a while now, and I think things are starting to look really exciting right now. Let me explain why I think this could be huge:
They produce Thorium-228 and Lead-212—two important alpha-emitting isotopes used in next-generation cancer treatment (Targeted Alpha Therapy). Think of it as a precision weapon against cancer cells that delivers a high dose of radiation directly to the tumor, with minimal damage to healthy tissue. This is a field that’s growing extremely fast.
The main catalyst right now:
The AlphaOne facility at Herøya is complete (mechanical completion in April 2026) and is in the commissioning phase. They plan to start commercial production in Q3 2026—in other words, very soon. This is their first major commercial facility, and it is built on patented technology that is both environmentally friendly and cost-effective (no reactor required).
Strong contracts and partners:
They already have several multi-year agreements in place. The most exciting one is with AdvanCell—an Australian clinical-stage company developing Lead-212 therapies for prostate cancer. The agreement has been extended to approximately 150 million kroner over five years.
And the best part? AdvanCell has entered into a strategic partnership with Eli Lilly (yes, the pharmaceutical giant) to develop more such therapies. When Lilly brings its resources and expertise to the table, it validates the entire platform. That means increased demand for exactly what Thor Medical delivers.
They also have agreements with other players such as RadioMedix and Telix, so they’re building a solid portfolio of customers.
The market is crying out for a reliable supply of these isotopes.
Thor Medical is an early mover with a scalable facility.
Production will start soon, and revenue is expected to take off in the second half of 2026.
Their technology addresses a real bottleneck in a market that many believe will explode as more therapies come to market.
We’re talking about a Norwegian company that sits at the heart of the value chain for something that could revolutionize cancer treatment. With AlphaOne soon to be operational, strong contracts, and interest from Big Pharma through its partners, it feels like we’re on the cusp of something big.